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Summary Although pseudoseizures are a cause of drug toxicity (as escalating doses
are used in an attempt to suppress seemingly intractable spells), in this brief re-
port the exact converse is argued: namely, that a sub-group of pseudoseizures may
arise as a reversible idiosyncratic toxic side-effect of GABAergic anticonvulsants. The
term ‘‘organic pseudoseizures’’ is used to denote this group of medication related
behavioural alterations.
© 2003 Published by Elsevier Ltd on behalf of BEA Trading Ltd.
Introduction
Pseudoseizures (‘‘hysterical ﬁts’’) are a common
clinical problem for family physicians, internists,
psychiatrists, neurologists and neurosurgeons. Re-
grettably, the term ‘‘pseudoseizure’’ is ﬁrmly en-
trenched in the vernacular of modern clinical neu-
rology. It is a word with signiﬁcant psychological,
social and clinical implications. From the patient’s
perspective, the diagnosis of pseudoseizures may
result in diminished self-esteem, loss of insurance
coverage, inappropriate medication adjustments,
and strained interactions with members of the
health care team. When a patient with history of
pseudoseizures visits an emergency room, they
are sometimes treated as ‘‘fakers’’, less deserving
than people with ‘‘true seizures’’. To lessen the un-
fortunate connotations surrounding this diagnostic
entity, various other terms have been introduced,
including non-epileptic attack disorder (NEAD).1
However, the much-needed destigmatization of
pseudoseizures requires more than a change in
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nomenclature. It requires fundamental molecular
level advances concerning the psychopharmacol-
ogy of pseudoseizures as a behavioural disorder.
Accordingly, medication effects in patients with
pseudoseizures were studied. As part of this anal-
ysis, the novel concept of pseudoseizures as a
possible medication-induced side-effect emerged.
Pseudoseizures are paroxysmal episodes of al-
tered behaviour (movements, sensations) without
concomitant seizure-associated electroencephalo-
graphic changes.2 Although many have suggested
that pseudoseizures are a cause of drug toxicity (as
escalating doses are used in an attempt to suppress
seemingly intractable spells), in this short com-
munication the exact converse is argued: namely,
that a sub-group of pseudoseizures may arise as
an idiosyncratic toxic side-effect of anticonvul-
sants that are active at the gamma-aminobutyric
acid (GABA-A) receptor. The term ‘‘organic
pseudoseizures’’ is used to denote this group of
medication related NEAD. To ascertain the signif-
icance of possible GABAergic-induced NEADs, a
prospective study was performed correlating the
occurrence of NEADs with the co-administration of
GABAergic anticonvulsant agents.
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Methods and results
Of 352 consecutive patients evaluated in the
Kingston General Hospital Epilepsy Clinic during the
ﬁrst 8 months of 1999, 56 (16%) had pseudoseizures,
either in isolation or in association with seizures.
Of these 56 patients, 5 (9%) had pseudoseizures
that had commenced concomitantly (within 14—29
days) with the administration of speciﬁc GABAer-
gic anticonvulsant agents (e.g. clobazam [1/5],
clonazepam [1/5], primidone [1/5], vigabatrin
[2/5]) and which had resolved following discon-
tinuation of the medication (within 18—37 days);
these pseudoseizures were superimposed upon
an underlying seizure disorder of greater than 4
years duration without previous documentation of
non-epileptic attacks. All ﬁve affected individu-
als had a pre-existing diagnosis of complex-partial
seizures. An additional 12/56 patients in the pseu-
doseizure group were also receiving one or more of
these four GABAergic agents, but with no time cor-
relation between the administration of the agent
and the onset of the non-epileptic attacks. The
administration of carbamazepine, phenytoin, val-
proate, or lamotrigine was not associated with the
initiation of non-epileptic attacks in any patient
seen during the study period.
Discussion
Pseudoseizures have a poorly deﬁned epidemi-
ology, reﬂecting difﬁculties in establishing their
prevalence and incidence. Various estimates sug-
gest that 9—24% of patients being evaluated for
epileptic seizures actually have pseudoseizures;
thus, pseudoseizures are a signiﬁcant health care
problem.1 Although concepts concerning the ae-
tiology of pseudoseizures are still in evolution,
psychological explanations currently predominate,
with pseudoseizures being regarded as a learned
pattern of behaviour developed to enable a per-
son to deal with environmental stressors.3 Gates,
however, recognized the heterogeneity of pseudo-
seizures, categorizing non-epileptic spells as either
physiologic (e.g. parasomnias) or psychological
(e.g. depression, conversion disorder).4,5
To this classiﬁcation system, the present study of-
fers a new category: pharmacologic. Five patients
with no pre-existing psychopathology were iden-
tiﬁed. All ﬁve patients developed pseudoseizures
concomitant with the introduction of a GABAergic
anticonvulsant drug; all had abatement of the pseu-
doseizures following discontinuation of the agent.
None had previously experienced pseudoseizures;
none had further pseudoseizures in 24 months of
follow-up. Thus, there was a deﬁnite correlation
between the duration of pseudoseizure susceptibil-
ity and the administration of a GABAergic agent.
The observations of this study suggest that
GABAergic anticonvulsants may produce non-epi-
leptic attacks as a side-effect. Of the traditional
anticonvulsants, primidone and phenobarbital are
prototypic GABAergic agents. The barbiturate
mechanism of action is via prolonged chloride
channel opening at the GABA-A receptor com-
plex. The capacity of barbiturates to produce be-
havioural side-effects has been well documented,
producing emotional outbursts, signiﬁcant depres-
sion and personality changes in both children and
adults. Benzodiazepines (clonazepam, clobazam)
are also GABAergic agents, binding to the GABA-A
receptor and increasing the rate of ion channel
opening frequency. Irritability and aggressiveness
have all been documented as side-effects of ben-
zodiazepine administration. Among the new anti-
convulsants, vigabatrin is an agent with signiﬁcant
GABAergic properties via irreversible inhibition
of the GABA transaminase enzyme, leading to in-
creased GABA levels. Over the past decade the
ability of vigabatrin to elicit psychiatric reactions
has been noted.6 Depression, confusion and other
behavioural abnormalities also accompany vigaba-
trin use. (In addition, GABAergic processes may also
play a role in other neuropsychiatric disorders, in-
cluding Huntington’s Disease, and schizophrenia.7)
Therefore, neurochemical evidence suggests a ca-
pacity for GABAergic agents to produce behavioural
side-effects.
Other authors have suggested the possibility of
anticonvulsant-induced episodic behavioural dis-
orders. For example, Rabe described a patient in
whom anticonvulsant medication led to the ‘‘ini-
tiation of hysterical ﬁts’’.8 He concluded that
there was a mutual antagonism between seizures
and psychiatric problems and that as the seizures
improved, the psychiatric problem emerged. Nei-
dermeyer et al. also suggested that pseudoseizures
may be enhanced by anticonvulsants.9,10 He pos-
tulated that pre-existing ‘‘cerebral dysfunction’’
predispose certain individuals to exhibit pseudo-
seizures and that diffuse electroencephalographic
slow wave activity arising from anticonvulsant tox-
icity facilitates the expression of pseudoseizures.
Neither Rabe nor Neidermeyer restricted the
side-effect to a particular anticonvulsant drug.
Conclusions
In conclusion, the existence of ‘‘organic pseudo-
seizures’’ as a reversible drug-induced side-effect
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has been identiﬁed. Barbiturates, benzodiazepines
and vigabatrin produce behavioural side-effects;
pseudoseizures are a behavioural problem. Extend-
ing the conclusions of this study to other agents
(e.g. tiagabine) is not within the scope of the
available data. Since patients with complex partial
epilepsy are usually on multiple medications with
frequent medication adjustments, time linked rela-
tionships between the onset of pseudoseizures and
the administration of a particular anticonvulsant
agent may go unrecognized. Nevertheless, the iden-
tiﬁcation of drug-induced organic pseudoseizures
is a signiﬁcant observation that is important to the
management of patients presenting with atypical
spells suggestive of non-epileptic seizures.
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